Paper16601286
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM and 12 others. Endocr Relat Cancer, 2006. Cited by 116 papers, by iCite.
Cite this record
ConductScience Library. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Papers, record 16601286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16601286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 3-Hydroxysteroid Dehydrogenases | Major topic |
| Adenocarcinoma | Major topic |
| Hydroxyprostaglandin Dehydrogenases | Major topic |
| Prostate | Major topic |
| Prostatic Neoplasms | Major topic |
| Receptors, Androgen | Major topic |
| Aged | |
| Aldo-Keto Reductase Family 1 Member C3 | |
| Antibodies, Monoclonal | |
| Blotting, Western | |
| Epithelial Cells | |
| Gene Expression Regulation, Enzymologic | |
| Humans | |
| Immunoenzyme Techniques | |
| Male | |
| Middle Aged | |
| Reverse Transcriptase Polymerase Chain Reaction | |
| Stromal Cells | |
| Tumor Cells, Cultured |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 97044 | NCI NIH HHS | United States | PubMed | PubMed | |
| DK 47015 | NIDDK NIH HHS | United States | R01DK047015 | PubMed and NIH | NIH RePORTER |
| DK 54925 | NIDDK NIH HHS | United States | R01DK054925 | PubMed and NIH | NIH RePORTER |
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42390142 | Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. | Oncologist | 2026 | https://conductscience.org/library/papers/42390142 | PubMed |
| 40127205 | Inhibition of Steroidogenesis in Prostate Cancer Cells by Both a Natural and Another Synthetic Steroid. | Drug Dev Res | 2025 | https://conductscience.org/library/papers/40127205 | PubMed |
| 38421088 | Activation of testosterone-androgen receptor mediates cerebrovascular protection by photobiomodulation treatment in photothrombosis-induced stroke rats. | CNS Neurosci Ther | 2024 | https://conductscience.org/library/papers/38421088 | PubMed |
| 37900995 | Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/37900995 | PubMed |
| 37428858 | Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model. | J Med Chem | 2023 | https://conductscience.org/library/papers/37428858 | PubMed |
| 36845727 | A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma. | Front Oncol | 2023 | https://conductscience.org/library/papers/36845727 | PubMed |
| 31672619 | The role of adrenal derived androgens in castration resistant prostate cancer. | J Steroid Biochem Mol Biol | 2020 | https://conductscience.org/library/papers/31672619 | PubMed |
| 31052459 | Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer. | J Clin Med | 2019 | https://conductscience.org/library/papers/31052459 | PubMed |
| 31015346 | OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31015346 | PubMed |
| 30241348 | Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30241348 | PubMed |
| 30137266 | Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes. | Endocr Rev | 2019 | https://conductscience.org/library/papers/30137266 | PubMed |
| 30012349 | AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders. | Mol Cell Endocrinol | 2019 | https://conductscience.org/library/papers/30012349 | PubMed |
| 28865807 | Intracrine androgen biosynthesis, metabolism and action revisited. | Mol Cell Endocrinol | 2018 | https://conductscience.org/library/papers/28865807 | PubMed |
| 28367977 | Riboflavin deficiency induces a significant change in proteomic profiles in HepG2 cells. | Sci Rep | 2017 | https://conductscience.org/library/papers/28367977 | PubMed |
| 27486833 | Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. | J Med Chem | 2016 | https://conductscience.org/library/papers/27486833 | PubMed |
| 26797685 | Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. | Horm Cancer | 2016 | https://conductscience.org/library/papers/26797685 | PubMed |
| 26429394 | Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. | J Steroid Biochem Mol Biol | 2016 | https://conductscience.org/library/papers/26429394 | PubMed |
| 26116659 | AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. | Blood | 2015 | https://conductscience.org/library/papers/26116659 | PubMed |
| 26032458 | Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). | J Steroid Biochem Mol Biol | 2015 | https://conductscience.org/library/papers/26032458 | PubMed |
| 25379460 | Steroid hormone synthetic pathways in prostate cancer. | Transl Androl Urol | 2013 | https://conductscience.org/library/papers/25379460 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKR1C3 | 8644 | PubTator's text mining | https://conductscience.org/library/genes/8644 | NCBI Gene |
| AKR1C4 | 1109 | PubTator's text mining | https://conductscience.org/library/genes/1109 | NCBI Gene |
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16601286
GET https://conductscience.org/api/papers/v1/16601286/cited_by?page=2